- Home
- FSFG vs CHRS Comparison
FSFG vs CHRS Comparison
Compare FSFG & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSFG
- CHRS
- Stock Information
- Founded
- FSFG 2008
- CHRS 2010
- Country
- FSFG United States
- CHRS United States
- Employees
- FSFG N/A
- CHRS N/A
- Industry
- FSFG Savings Institutions
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FSFG Finance
- CHRS Health Care
- Exchange
- FSFG Nasdaq
- CHRS Nasdaq
- Market Cap
- FSFG 165.5M
- CHRS 84.2M
- IPO Year
- FSFG 2008
- CHRS 2014
- Fundamental
- Price
- FSFG $25.92
- CHRS $0.90
- Analyst Decision
- FSFG Strong Buy
- CHRS Buy
- Analyst Count
- FSFG 3
- CHRS 3
- Target Price
- FSFG $31.50
- CHRS $4.68
- AVG Volume (30 Days)
- FSFG 59.3K
- CHRS 1.3M
- Earning Date
- FSFG 07-24-2025
- CHRS 08-07-2025
- Dividend Yield
- FSFG 2.44%
- CHRS N/A
- EPS Growth
- FSFG 159.10
- CHRS N/A
- EPS
- FSFG 2.81
- CHRS N/A
- Revenue
- FSFG $75,839,000.00
- CHRS $272,251,000.00
- Revenue This Year
- FSFG $0.06
- CHRS N/A
- Revenue Next Year
- FSFG $8.60
- CHRS $99.43
- P/E Ratio
- FSFG $9.26
- CHRS $2.07
- Revenue Growth
- FSFG N/A
- CHRS 19.87
- 52 Week Low
- FSFG $18.21
- CHRS $0.66
- 52 Week High
- FSFG $30.94
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- FSFG 54.37
- CHRS 59.04
- Support Level
- FSFG $25.57
- CHRS $0.73
- Resistance Level
- FSFG $26.51
- CHRS $0.82
- Average True Range (ATR)
- FSFG 0.66
- CHRS 0.04
- MACD
- FSFG 0.23
- CHRS 0.02
- Stochastic Oscillator
- FSFG 80.46
- CHRS 88.02
About FSFG First Savings Financial Group Inc.
First Savings Financial Group Inc provides various banking services to individuals and business customers in southern Indiana. The bank accepts deposits from the general public & uses those funds, along with other borrowings, mainly to originate a residential mortgage, commercial mortgage, construction, commercial business, & consumer loans, and to a lesser extent, to invest in mortgage-backed securities and other debt securities. The company conducts lending and deposit activities mainly with individuals and small businesses in its market area. The bank operates in two segments: core banking, which accounts for the majority of revenue, and SBA lending.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.